{
    "nct_id": "NCT04837677",
    "official_title": "A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* Adequate organ function (bone marrow, hepatic, renal, cardiovascular)\n* Left ventricular ejection fraction of ≥ 50%\n* Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use a highly effective method of contraception during the trial\n* Patients must have recovered from the effects of any prior cancer related therapy, radiotherapy or surgery (toxicity ≤ Grade 1)\n* All patients on prior investigational agents must wait at least 5 half-lives of the agent in question, or 28 days, whichever is longer before study entry\n* Most recent lab values meet the following criteria:\n\n  * Absolute neutrophil count > 1.0 x 10^3/μL;\n  * Platelet count > 75,000/μL;\n  * Hemoglobin > 9.0 g/dL\n* Histologically confirmed advanced or metastatic solid tumor indicated below that is relapsed, refractory, or intolerant to available therapies with known benefit:\n\n  * Sarcoma not amendable to curative treatment with surgery or radiotherapy;\n  * Melanoma (non-resectable or metastatic);\n  * Small cell lung cancer (extensive-stage);\n  * Non-small cell lung cancer;\n  * Triple negative breast cancer (histopathologically or cytologically confirmed).\n  * Esophageal cancer\n  * Cervical cancer\n  * Head and neck cancer\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known hypersensitivity to any of the components of PRT1419\n* Primary malignancies of the CNS, or uncontrolled CNS metastases, including impending spinal cord compression\n* Female patients who are pregnant or lactating\n* Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption\n* Mean QTcF interval of >480 msec\n* History of heart failure, additional risk factors for arrhythmias or requiring concomitant medications that prolong the QT/QTc interval\n* HIV positive; known active hepatitis B or C\n* Uncontrolled intercurrent illnesses\n* Treatment with strong inhibitors of CYP2C8\n* Prior exposure to an MCL1 inhibitor\n* History of another malignancy except:\n\n  * Malignancy treated with curative intent with no known active disease for >2 years at study entry;\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease;\n  * Adequately treated carcinoma in situ without evidence of disease;\n  * Other concurrent low-grade malignancies (i.e chronic lymphocytic leukemia (Rai 0)) may be considered after consultation with Sponsor.",
    "miscellaneous_criteria": ""
}